Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Nat Med Retrieve available abstracts of 45 articles: HTML format

Single Articles

November 2024
1. ALBAN TJ, Riaz N, Parthasarathy P, Makarov V, et al
   Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.
   Nat Med. 2024;30:3209-3222.
   PubMed     Abstract available
   
   
   
2. WANG C, Shao J, He Y, Wu J, et al
   Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
   Nat Med. 2024;30:3184-3195.
   PubMed     Abstract available
   
   
   September 2024
3. LI N, Wang SY
   Navigating treatment combinations in small-cell lung cancer.
   Nat Med. 2024 Sep 18. doi: 10.1038/s41591-024-03255.
   PubMed    
   
   
   
4. JEE J, Brannon AR, Singh R, Derkach A, et al
   DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
   Nat Med. 2024;30:2499-2507.
   PubMed     Abstract available
   
   
   August 2024
5. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
   Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
   Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03178.
   PubMed    
   
   
   July 2024
6. CHENG Y, Chen J, Zhang W, Xie C, et al
   Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
   Nat Med. 2024 Jul 11. doi: 10.1038/s41591-024-03132.
   PubMed     Abstract available
   
   
   June 2024
7. PETERS S, Gadgeel SM, Mok T, Nadal E, et al
   Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
   Nat Med. 2024 Jun 19. doi: 10.1038/s41591-024-03008.
   PubMed     Abstract available
   
   
   
8. WIDMAN AJ, Shah M, Frydendahl A, Halmos D, et al
   Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
   Nat Med. 2024;30:1655-1666.
   PubMed     Abstract available
   
   
   May 2024
9. SHIELDS MD, Lovly CM
   Refining neoadjuvant immunotherapy for resectable lung cancer.
   Nat Med. 2024 May 13. doi: 10.1038/s41591-024-03001.
   PubMed    
   
   
   
10. ZENG Y, Hu CH, Li YZ, Zhou JS, et al
    Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02929.
    PubMed     Abstract available
    
    
    April 2024
11. SCHULER M, Cuppens K, Plones T, Wiesweg M, et al
    Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965.
    PubMed     Abstract available
    
    
    
12. TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al
    Risk-based lung cancer screening performance in a universal healthcare setting.
    Nat Med. 2024;30:1054-1064.
    PubMed     Abstract available
    
    
    
13. VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al
    Demographic bias in misdiagnosis by computational pathology models.
    Nat Med. 2024;30:1174-1190.
    PubMed     Abstract available
    
    
    
14. SINGHAL A, Li BT, O'Reilly EM
    Targeting KRAS in cancer.
    Nat Med. 2024;30:969-983.
    PubMed     Abstract available
    
    
    
15. GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al
    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
    Nat Med. 2024;30:984-989.
    PubMed     Abstract available
    
    
    February 2024
16. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
    PubMed     Abstract available
    
    
    October 2023
17. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
    Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
    PubMed     Abstract available
    
    
    
18. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627.
    PubMed    
    
    
    
19. ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al
    ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
    Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598.
    PubMed     Abstract available
    
    
    September 2023
20. CHO BC, Kim DW, Spira AI, Gomez JE, et al
    Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
    Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554.
    PubMed     Abstract available
    
    
    July 2023
21. LIU SM, Tu HY, Wei XW, Yan HH, et al
    First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
    Nat Med. 2023 Jul 24. doi: 10.1038/s41591-023-02461.
    PubMed     Abstract available
    
    
    
22. GUTIERREZ M, Lam WS, Hellmann MD, Gubens MA, et al
    Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
    Nat Med. 2023 Jul 10. doi: 10.1038/s41591-023-02385.
    PubMed     Abstract available
    
    
    June 2023
23. SIKKEMA L, Ramirez-Suastegui C, Strobl DC, Gillett TE, et al
    An integrated cell atlas of the lung in health and disease.
    Nat Med. 2023;29:1563-1577.
    PubMed     Abstract available
    
    
    May 2023
24. GOLDSMITH KC, Park JR, Kayser K, Malvar J, et al
    Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
    Nat Med. 2023;29:1092-1102.
    PubMed     Abstract available
    
    
    April 2023
25. AL-SAWAF O, Weiss J, Skrzypski M, Lam JM, et al
    Body composition and lung cancer-associated cachexia in TRACERx.
    Nat Med. 2023 Apr 12. doi: 10.1038/s41591-023-02232.
    PubMed     Abstract available
    
    
    
26. 
    High-resolution circulating tumor DNA testing predicts survival in metastatic lung cancer clinical trials.
    Nat Med. 2023;29:797-798.
    PubMed    
    
    
    
27. 
    Clinicogenomic landscape of morphological evolution in lung adenocarcinoma.
    Nat Med. 2023;29:795-796.
    PubMed    
    
    
    
28. KARASAKI T, Moore DA, Veeriah S, Naceur-Lombardelli C, et al
    Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.
    Nat Med. 2023;29:833-845.
    PubMed     Abstract available
    
    
    
29. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    PubMed     Abstract available
    
    
    March 2023
30. CONROY M, Forde PM
    Advancing neoadjuvant immunotherapy for lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02246.
    PubMed    
    
    
    
31. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed     Abstract available
    
    
    
32. ASSAF ZJF, Zou W, Fine AD, Socinski MA, et al
    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02226.
    PubMed     Abstract available
    
    
    February 2023
33. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    PubMed     Abstract available
    
    
    November 2022
34. JEE J, Lebow ES, Yeh R, Das JP, et al
    Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
    Nat Med. 2022;28:2353-2363.
    PubMed     Abstract available
    
    
    October 2022
35. BAJAJ SS, Pan M, Potter AL, Yang CJ, et al
    Cigarette package labels to promote lung cancer screening.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02042.
    PubMed    
    
    
    September 2022
36. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2022 Sep 12. pii: 10.1038/s41591-022-01962.
    PubMed     Abstract available
    
    
    
37. PETERS S, Dziadziuszko R, Morabito A, Felip E, et al
    Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
    Nat Med. 2022;28:1831-1839.
    PubMed     Abstract available
    
    
    August 2022
38. GOGISHVILI M, Melkadze T, Makharadze T, Giorgadze D, et al
    Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
    Nat Med. 2022 Aug 25. pii: 10.1038/s41591-022-01977.
    PubMed     Abstract available
    
    
    April 2022
39. O'LEARY K
    New treatment option for early-stage lung cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00055.
    PubMed    
    
    
    
40. KIM ES, Velcheti V, Mekhail T, Yun C, et al
    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
    Nat Med. 2022 Apr 14. pii: 10.1038/s41591-022-01754.
    PubMed     Abstract available
    
    
    February 2022
41. DEROSA L, Routy B, Thomas AM, Iebba V, et al
    Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01655.
    PubMed     Abstract available
    
    
    November 2021
42. FORDE PM, Anagnostou V, Sun Z, Dahlberg SE, et al
    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Nat Med. 2021;27:1910-1920.
    PubMed     Abstract available
    
    
    August 2021
43. CREELAN BC, Wang C, Teer JK, Toloza EM, et al
    Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01462.
    PubMed     Abstract available
    
    
    
44. VEATCH JR, Simon S, Riddell SR
    Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01445.
    PubMed    
    
    
    
45. WANG M, Herbst RS, Boshoff C
    Toward personalized treatment approaches for non-small-cell lung cancer.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01450.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.